| Autor: |
Andrea D’Arienzo, Annarita Verrazzo, Martina Pagliuca, Fabiana Napolitano, Sara Parola, Martina Viggiani, Roberta Caputo, Fabio Puglisi, Mario Giuliano, Lucia Del Mastro, Grazia Arpino, Michelino De Laurentiis, Filippo Montemurro |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
EClinicalMedicine, Vol 62, Iss , Pp 102113- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2589-5370 |
| DOI: |
10.1016/j.eclinm.2023.102113 |
| Popis: |
Summary: Antibody–drug conjugates (ADCs) represent a novel and evolving class of antineoplastic agents, constituted by monoclonal antibody linked to biologically active drugs, delivering cytotoxic compounds at the tumor site, reducing the likelihood of systemic exposure and toxicity. They are generally well tolerated, nevertheless some predictable adverse reactions need careful monitoring and timely approach. These include neutropenia, nausea and vomiting, alopecia, diarrhea, left ventricular dysfunction, ILD/pneumonitis. The mechanisms leading to drug-associated toxicities are summarized, and prophylaxis protocols and appropriate management strategies are proposed, based on current literature. This review aims to collect the most updated evidence on toxicities potentially occurring during breast cancer treatment with approved or under clinical investigation (advanced stage) ADCs. A focus is dedicated to monitoring protocols and clinical management, aimed at preventing and/or promptly address relevant problems, in order to avoid premature discontinuation or improper dose reduction. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
